ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing...
Read More Details
Finally We wish PressBee provided you with enough information of ( Antengene to Present Latest Clinical Results from Two Studies in CPI-resistant Solid Tumors at ASCO 2025 )
Also on site :
- Stocks rally and oil dips after report says Iran is looking to de-escalate its conflict with Israel
- Oil prices up after reports of 3 ships on fire in Gulf of Oman near the strait of Hormuz
- 'Days of Our Lives' Mary Beth Evans Honors 'Legend' Stephen Nichols on 40th Anniversary: "What a Ride'